Use of continuous glucose monitoring to introduce adjunctive pramlintide therapy in a patient with type 1 diabetes: A case study

Abstract

AbstractPurpose: To report the successful use of a continuous glucose monitoring system (CGMS) in helping a patient with type 1 diabetes initiate a new diabetes therapy, pramlintide, which improves glycemic control.Data sources: Case report, diagnostic evidence, and scientific literature.Conclusions: CGMS data before and 3 months after pramlintide initiation supported the changes felt by the patient. Diurnal and postprandial glucose excursions decreased with a resultant decrease in A1C from 9% to 7.4%. Additionally, body weight decreased by 8 lbs and hypoglycemic events declined markedly. No nocturnal hypoglycemic events occurred during the observation period.Implications for practice: Given the serious and chronic nature of diabetes, it is paramount for the patient and healthcare provider to develop and modify as needed treatment regimens that help the patient achieve and maintain glycemic control over time—a difficult task even in the motivated patient. In patients with type 1 diabetes, pramlintide can further improve glycemic control and CGMS can be a beneficial tool for monitoring that change.